DOCSLIB.ORG

Simultaneous Polysubstance Use Among Danish 3,4Methylenedioxymethamphetamine and Hallucinogen Users: Combination Patterns and Pr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Simultaneous Polysubstance Use Among Danish 3,4Methylenedioxymethamphetamine and Hallucinogen Users: Combination Patterns and Pr human psychopharmacology Hum. Psychopharmacol Clin Exp 2012; 27: 352–363. Published online 14 June 2012 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/hup.2234 Simultaneous polysubstance use among Danish 3,4- methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases Cecilie L. Licht1*, Maria Christoffersen1, Mads Okholm1,LærkeDamgaard1, Anders Fink-Jensen2, Gitte M. Knudsen1 and David Erritzoe1 1Neurobiology Research Unit (NRU) and Center for Integrated Molecular Brain Imaging (Cimbi), University of Copenhagen and Rigshospitalet, Copenhagen, Denmark 2Psychiatric Centre Copenhagen and Laboratory of Neuropsychiatry, Department O, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark Objective To describe patterns of simultaneous polysubstance use (SPU) among Danish 3,4-methylenedioxymethamphetamine (MDMA) (“Ecstasy”) and hallucinogen users. Methods A cross-sectional survey of 98 active MDMA and/or hallucinogen users recruited through homepage advertisements, flyers, and word of mouth in Denmark. Lifetime and recent substance use and SPU at last recalled use was described by structured interviews. Hair samples from a subset of participants were analyzed for MDMA. Results The participants had used an average of 12.6 (95% confidence interval: 11.7–13.4) psychoactive substances during their lifetime. SPU was prevalent among MDMA, D-lysergic acid diethylamide (LSD), and psilocybin users, in particular with alcohol and cannabis. Among MDMA users, 69% had combined MDMA with amphetamines, 56% with hallucinogens, and 47% with cocaine. At last recalled use, MDMA was taken with 2.1 Æ 1.2 substances in 32 different combinations. The participants preferred specific drug combinations and named several, which in their experience enhanced or counteracted each other. Alcohol and cannabis were typically used before, during, and after MDMA, LSD, and psilocybin, whereas amphetamines were predominantly taken before these substances. When LSD was combined with MDMA, the majority took MDMA after LSD. Conclusions Simultaneous polysubstance use was common among Danish MDMA and hallucinogen users, and patterns of preferred substance combinations were evident. Copyright © 2012 John Wiley & Sons, Ltd. key words—substance-related disorders; 3,4-methylenedioxymethamphetamine; ecstasy; hallucinogens; designer drugs; street drugs INTRODUCTION particular, the simultaneous use of several drugs (simul- Substance-related disorders may have severe detrimental taneous polysubstance use, SPU) during the course of a effects on the health, social relationships, and employ- single drug use session is common among street drug ment of substance users, leading to substantial human users (Barrett et al., 2006; EMCDDA, 2009; Tossmann and financial loss to society. Many street drug users take et al., 2001) and may increase drug consumption (Barrett several different substances during their lifetime, a et al., 2006), morbidity and mortality from substance use (EMCDDA, 2009; Schifano et al., 2003), as well as phenomenon known as polysubstance use (EMCDDA, fl 2009; Tossmann et al., 2001; Wu et al., 2006). In in uence the development of drug tolerance in complex ways (Parrott, 2005). Often, particular substances are combined to enhance psychoactive effects or to relieve *Correspondence to: Dr. C. L. Licht, Neurobiology Research Unit (NRU) and unwanted after effects (Boys et al., 2001; Winstock Center for Integrated Molecular Brain Imaging (Cimbi), University of Copenha- et al., 2001). Whereas distinct characteristics of SPU gen and Rigshospitalet, Section 9201, Blegdamsvej 9, 2100 Copenhagen O, Denmark. Tel: +45 35456712; Fax: +45 35456713. E-mail: [email protected] have been described for different groups of street drug users and for users of particular substances including Dr. D. Erritzoe, Neuropsychopharmacology Unit, Imperial College London, 3,4-methylenedioxymethamphetamine (MDMA) (Barrett Burlington-Danes Building, Hammersmith Campus, 160 Du Cane Road, London W12 0NN, UK. Tel: +44 02075947047; Fax: +44 02075946548. et al., 2005; Tossmann et al., 2001), few studies have E-mail: [email protected] examined the order of substance administration and Received 15 February 2012 Copyright © 2012 John Wiley & Sons, Ltd. Accepted 3 May 2012 simultaneous polysubstance use among mdma users 353 the doses used during SPU. Given that substances can for LSD among 16–44-year olds (Ekholm et al., 2006). interact at many functional levels (pharmacokinetic However, in the dance club environment of European and pharmacodynamic) and that such interactions are metropolises, past month and lifetime prevalence rates affected by relative timing and dosage, this type of of hallucinogens of 8.1–21.6% and 21.1–66.8%, respec- information is important in understanding the biologi- tively, have been found (Tossmann et al., 2001). cal bases and effects of specific SPU patterns. Aims of the study MDMA is a widely used substance of abuse among teenagers and young adults with a past year and life- The aim of the present study was to examine patterns time prevalence of 1.7% and 5.8%, respectively, of lifetime and recent SPU, including drug order, among 15–34-year olds in the EU (EMCDDA, dosing, and adverse effects of MDMA use, among 2010). In Denmark (a member of the EU), the past year Danish MDMA and hallucinogen users. A detailed prevalence in 2010 was 0.8% among 16—34-year and qualitative description of SPU patterns may in olds (Sundhedsstyrelsen, 2010). MDMA exerts its the light of known psychopharmacological effects of main effects on serotonin (5-hydroxytryptamine, 5-HT), combining specific drugs further understanding of dopamine, and norepinephrine transporters, releasing SPU involving MDMA and hallucinogens. monoamines into the extracellular space, and has psychostimulant, empathogenic, and mild hallucinogenic METHODS properties (Capela et al., 2009; Gudelsky and Yamamoto, 2008). When used repeatedly and in high Participants doses, MDMA may have neurotoxic effects on seroto- Young Danish adults between the age of 18 and nergic neurons, although this contention is a subject of 35 years, who reported a lifetime history of at least 15 ongoing debate (Baumann et al., 2007; Capela et al., illicit drug experiences (excluding cannabis) and use 2009; Kish et al., 2010; Thomasius et al., 2003). The of MDMA or hallucinogens (at least once) within the use of MDMA may cause acute hyperthermia, which past 12 months, were included in the study. Participants exacerbates longer term adverse effects on memory were recruited between November 2005 and April 2008 and mood (Parrott, 2006). Polysubstance use is reported through advertisements posted on homepages used by by nearly all MDMA users and includes alcohol, nicotine, Danish hallucinogen and MDMA users and on flyers cannabis, amphetamines, cocaine, and hallucinogens distributed at music events, as well as by word of (Carlson et al., 2005; Parrott et al., 2001; Topp et al., mouth. A total of 284 subjects expressed interest in 1999). In particular, psychostimulant and hallucinogen the study, and 166 met the inclusion criteria. Interviews use has been significantly related to extent of MDMA were completed with 98 (87% male, 13% female) parti- use (Hammersley et al., 1999). Simultaneous use of cipants. It was not possible to schedule the remaining MDMA and other psychoactive substances was prevalent 68 for interview because of practical limitations. Each among participants in the European and Canadian techno subject provided informed consent and received a finan- dance scene and included several kinds of compounds cial compensation of DKK 110/h (EUR 15/h) for the 2- (Barrett et al., 2005; Tossmann et al., 2001). Importantly, hour duration of the interviews. A subset of participants simultaneous use of alcohol and MDMA prolonged was also included in a positron emission tomography feelings of euphoria in a controlled clinical experiment (PET) study (Erritzoe et al., 2011). The Research Ethics (Hernandez-Lopez et al., 2002) and may increase abuse Committee for the Capital Region of Denmark (H-KF-01- liability of MDMA (Jones et al., 2010). 124/04) approved the study. Hallucinogens are a group of perception-altering substances including psilocybin (“magic”) mushrooms, Structured interviews mescaline (peyote cacti), and ayahuasca, as well as A modified Danish version of the Customary Drinking semi-synthetic compounds such as D-lysergic acid and Drug Use Record (CDDR) domain “use frequency diethylamide (LSD), which exert their main effects as and quantity” was used to describe the participants’ agonists at the 5-HT2A receptor (Halpern, 2003; alcohol and substance use in details (Brown et al., Nichols, 2004). The use of hallucinogenic compounds 1998). The CDDR substance use domain collects in the general population is less prevalent than MDMA information on recent (past 3 months) and lifetime with past year and lifetime prevalence of 0.2–5.9% and alcohol and substance use (quantity and frequency of 0.3–14.1% for psilocybin mushrooms, and “very low” 13 specified substance types and any additional drugs and 0–6.1% for LSD among 15–34-year olds in the EU named by the participant), age of initiation, and doses (EMCDDA, 2010). In Denmark, the past year prevalence typically administered. The CDDR substance use in 2005 was 0.4% for psilocybin mushrooms and 0.1% domain had 1-week test–retest reliability coefficients Copyright © 2012 John Wiley & Sons, Ltd. Hum. Psychopharmacol Clin Exp 2012; 27: 352–363. DOI:
Load more

Recommended publications
  • Effects of Stress-Induced Depression on Parkinson's Disease
    Effects of stress-induced depression on Parkinson’s disease symptomatology A dissertation submitted to the Division of Research and Advanced Studies of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Ph.D.) in the Graduate Program in Neuroscience of the College of Medicine 2011 By Ann Marie Hemmerle B.S., University of Dayton Advisor: Kim B. Seroogy, Ph.D. Committee Chair: Neil Richtand, M.D., Ph.D. James P. Herman, Ph.D. Kathy Steece-Collier, Ph.D. Aaron Johnson, Ph.D. Abstract Parkinson’s disease (PD) is a chronic neurodegenerative disorder that primarily affects dopaminergic neurons of the nigrostriatal pathway resulting in debilitating motor symptoms. Parkinson’s patients also have a high risk of comorbid depression, though this aspect of the disorder is less well studied. Understanding the underlying pathology of the comorbidity is important in improving clinical treatments and the quality of life for PD patients. To address this issue, we have developed a new model combining the unilateral striatal 6-hydroxydopamine lesion model of PD with the chronic variable stress model (CVS) of depression. Dysfunction of the hypothalamic-pituitary-adrenal axis and its relationship to depression symptomatology is well established. Stress dysfunction may also have a role in the etiology of preclinical PD non- motor symptoms, and later in the course of the disease, may worsen motor symptoms. The combined model allows us to test the hypothesis that experimental depression exacerbates PD symptoms and to ascertain the mechanisms behind the increased neuronal loss. In the first study, we examined several temporal paradigms of the combined model.
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Personalized Treatment of Alcohol Dependence
    Curr Psychiatry Rep DOI 10.1007/s11920-012-0296-5 SUBSTANCE USE AND RELATED DISORDERS (JR MCKAY, SECTION EDITOR) Personalized Treatment of Alcohol Dependence Henry R. Kranzler & James R. McKay # Springer Science+Business Media, LLC 2012 Abstract Pharmacogenetic and adaptive treatment approaches Ondansetron . Sertraline . Adaptive trial designs . can be used to personalize care for alcohol-dependent patients. Adaptive protocol . Stepped care . Treatment algorithm Preliminary evidence shows that variation in the gene encoding the μ-opioid receptor moderates the response to naltrexone when used to treat alcohol dependence. Studies have also shown moderating effects of variation in the gene encoding Introduction the serotonin transporter on response to serotonergic treatment of alcohol dependence. Adaptive algorithms that modify alco- Traditionally, diagnostic tests and medical treatments have hol treatment based on patients’ progress have also shown been developed and evaluated using group data, a “one-size promise. Initial response to outpatient treatment appears to be fits all” approach that leaves little room for individual variation a particularly important in the selection of optimal continuing [1]. Personalized medicine, which uses individual features to care interventions. In addition, stepped-care algorithms can diagnose and treat disease, is of growing interest, having reduce the cost and burden of treatment while maintaining good produced notable successes in oncology and cardiology [2•, outcomes. Finally, matching treatment to specific problems 3]. To date, there have been fewer advances in the personalized present at intake or that emerge during treatment can also diagnosis and treatment of addictive disorders. However, on- improve outcomes. Although all of these effects require repli- going developments in genetics and pharmacogenetics and in cation and further refinement, the future of personalized care for the use of adaptive trial designs offer great potential to extend alcohol dependence appears bright.
    [Show full text]
  • A Nonlinear Relationship Between Cerebral Serotonin Transporter And
    The Journal of Neuroscience, March 3, 2010 • 30(9):3391–3397 • 3391 Cellular/Molecular A Nonlinear Relationship between Cerebral Serotonin Transporter and 5-HT2A Receptor Binding: An In Vivo Molecular Imaging Study in Humans David Erritzoe,1,3 Klaus Holst,3,4 Vibe G. Frokjaer,1,3 Cecilie L. Licht,1,3 Jan Kalbitzer,1,3 Finn Å. Nielsen,3,5 Claus Svarer,1,3 Jacob Madsen,2 and Gitte M. Knudsen1,3 1Neurobiology Research Unit and 2PET and Cyclotron Unit, University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark, 3Center for Integrated Molecular Brain Imaging, DK-2100 Copenhagen, Denmark, 4Department of Biostatistics, University of Copenhagen, DK-2200 Copenhagen, Denmark, and 5DTU Informatics, Technical University of Denmark, DK-2800 Lyngby, Denmark Serotonergic neurotransmission is involved in the regulation of physiological functions such as mood, sleep, memory, and appetite. Withintheserotonintransmittersystem,boththepostsynapticallylocatedserotonin2A(5-HT2A )receptorandthepresynapticserotonin transporter (SERT) are sensitive to chronic changes in cerebral 5-HT levels. Additionally, experimental studies suggest that alterations in either the 5-HT2A receptor or SERT level can affect the protein level of the counterpart. The aim of this study was to explore the covariation betweencerebral5-HT2A receptorandSERT invivointhesamehealthyhumansubjects.Fifty-sixhealthyhumansubjectswithameanage of 36 Ϯ 19 years were investigated. The SERT binding was imaged with [ 11C]3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)- 18 benzonitrile (DASB) and 5-HT2A receptor binding with [ F]altanserin using positron emission tomography. Within each individual, a regionalintercorrelationforthevariousbrainregionswasseenwithbothmarkers,mostnotablyfor5-HT2A receptorbinding.Aninverted U-shaped relationship between the 5-HT2A receptor and the SERT binding was identified. The observed regional intercorrelation for both the 5-HT2A receptor and the SERT cerebral binding suggests that, within the single individual, each marker has a set point adjusted through a common regulator.
    [Show full text]
  • [18F] Altanserin Bolus Injection in the Canine Brain Using PET Imaging
    Pauwelyn et al. BMC Veterinary Research (2019) 15:415 https://doi.org/10.1186/s12917-019-2165-5 RESEARCH ARTICLE Open Access Kinetic analysis of [18F] altanserin bolus injection in the canine brain using PET imaging Glenn Pauwelyn1*† , Lise Vlerick2†, Robrecht Dockx2,3, Jeroen Verhoeven1, Andre Dobbeleir2,5, Tim Bosmans2, Kathelijne Peremans2, Christian Vanhove4, Ingeborgh Polis2 and Filip De Vos1 Abstract 18 Background: Currently, [ F] altanserin is the most frequently used PET-radioligand for serotonin2A (5-HT2A) receptor imaging in the human brain but has never been validated in dogs. In vivo imaging of this receptor in the canine brain could improve diagnosis and therapy of several behavioural disorders in dogs. Furthermore, since dogs are considered as a valuable animal model for human psychiatric disorders, the ability to image this receptor in dogs could help to increase our understanding of the pathophysiology of these diseases. Therefore, five healthy laboratory beagles underwent a 90-min dynamic PET scan with arterial blood sampling after [18F] altanserin bolus injection. Compartmental modelling using metabolite corrected arterial input functions was compared with reference tissue modelling with the cerebellum as reference region. 18 Results: The distribution of [ F] altanserin in the canine brain corresponded well to the distribution of 5-HT2A receptors in human and rodent studies. The kinetics could be best described by a 2-Tissue compartment (2-TC) model. All reference tissue models were highly correlated with the 2-TC model, indicating compartmental modelling can be replaced by reference tissue models to avoid arterial blood sampling. Conclusions: This study demonstrates that [18F] altanserin PET is a reliable tool to visualize and quantify the 5- HT2A receptor in the canine brain.
    [Show full text]
  • Radioactive Isotope* in Clinical Medicine and Research Final Programme & Abstracts Book
    AT0200334 Radioactive Isotope* in Clinical Medicine and Research ESHS-AT--0031 25th International Symposium 8-11 January, 2002 Bad Gasiein, Austria Final Programme & Abstracts Book Organized by The Austrian Society of Nuclear Medicine and the Departments of Nuclear Medicine and Biomedical Engineering & Physics, University of Vienna http://www. akh-wien. ac. at/bg2002 Merck - kompetent in der Schilddri Euthyrox Jodthyrox Novothyral •« Jodid Merck Fachinformation siehe Innenteil PLEASE BE AWARE THAT ALL OF THE MISSING PAGES IN THIS DOCUMENT WERE ORIGINALLY BLANK Mi^Jx-T^aoM iiiiiiiiii RADIOACTIVE ISOTOPES in Clinical Medicine and Research 25th International Symposium Bad Gastein Austria 8 to 11 January 2002 Organized by The Austrian Society of Nuclear Medicine (ÖGN) and the Departments of Nuclear Medicine and Biomedical Engineering & Physics, University of Vienna Final Programme & Abstracts Book JODID MERCK 100 ng-Tabletten • Zusammensetzung: 1 Tablette enthält 130,8 ng Kaliumjodid, entsprechend 100 (ig Jod. 84 mg Laktose, Magnesiumstearat Cellulose. Maisstärke. Anwen- dungsgebiete: Behandlung des Jodmangelkropfes bei Neugeborenen und Kindern. Gegenanzeigen: Überempfindlichkeit gegen Jod. Manifeste Schilddrüsenüberfunktion. Latente Schilddrüsen- Überfunktion bei Joddosen über 150 ug/Tag. Schwangerschaft und Stillperiode: Wählend der Schwangerschaft und Stillperiode soll die Jodzufuhr fortgesetzt werden. EUTHYROX 50 u.g, 75 ug, 100 ug, 125 ug. 150 ug-Tabletten • Zusammensetzung: 1 Euthyrox 50ng/75ug/100ug/125ug/150ug-Tablette enthält 50
    [Show full text]
  • UC Berkeley UC Berkeley Electronic Theses and Dissertations
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Other Times I Can Barely See: The Effects of Hallucinogens on Vision and Attention Permalink https://escholarship.org/uc/item/7409s4th Author Baggott, Matthew John Publication Date 2010 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Other Times I Can Barely See: The Effects of Hallucinogens on Vision and Attention By Matthew John Baggott A dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy in Neuroscience in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Lynn C. Robertson, Chair Professor Dennis M. Levi Lecturer David E. Presti Assistant Professor Michael A. Silver Spring 2010 Abstract Other Times I Can Barely See: The Effects of Hallucinogens on Vision and Attention by Matthew John Baggott Doctor of Philosophy in Neuroscience University of California, Berkeley Professor Lynn C. Robertson, Chair In this dissertation, I used theories of serotonin to understand the effects of serotonergic hallucinogens on visual perception and attention. I began by studying hallucinatory syndromes in drug users in Chapter 1. Despite long-standing reports of prolonged or reoccurring perceptual changes in a subset of hallucinogen users, very little is known about Hallucinogen Persisting Perception Disorder (HPPD) and related visual abnormalities in hallucinogen users. I used an online questionnaire to document the prevalence, symptoms, and relationship to drug use of persisting unusual visual phenomena in hallucinogen users. 16,192 individuals viewed the information sheet, and 2,679 were included in the study. Most participants (61.7%) reported having experienced drug-free visual experiences that resembled hallucinogen effects.
    [Show full text]
  • Imaging the Neurochemistry of Alcohol and Substance Abuse
    539 NEUROIMAGING CLINICS OF NORTH AMERICA Neuroimag Clin N Am 17 (2007) 539–555 Imaging the Neurochemistry of Alcohol and Substance Abuse Diana Martinez, MDa,*, Jong-Hoon Kim, MDa, John Krystal, MDb, Anissa Abi-Dargham, MDa,c - Cocaine dependence Behavioral correlates of low D2/3 receptor Dopamine D2/3 receptors and dopamine binding potential transmission Alcohol dependence and presynaptic Functional significance of low D2/3 dopamine receptor binding in cocaine Alcohol dependence and the dopamine dependence transporter Behavior and dopamine transmission Serotonin and alcohol dependence Imaging cue-induced craving in cocaine Measures of GABA in alcohol dependence dependence Opioids and alcohol dependence Cocaine dependence and the dopamine - Heroin dependence transporter - Methamphetamine abuse Imaging studies of cocaine dependence - Methylenedioxymethamphetamine and other neurotransmitters (Ecstasy) abuse - Alcohol dependence - Hallucinogens - Dopamine D2/3 receptor and alcohol Summary dependence - References Positron emission tomography (PET) and single we briefly overview the concepts that are needed photon emission computed tomography (SPECT) to interpret these studies. The PET radiotracers use radiotracers to image molecular targets in the most frequently used in substance abuse research human brain. These techniques have been applied are those that label the dopamine type 2/3 (D2/3) over the last decade to study addiction and provide receptors of the striatum, such as the antagonists an important body of knowledge about the neuro-
    [Show full text]
  • Molecular Targeting with Radionuclides: State of the Science*
    CONTINUING EDUCATION Molecular Targeting with Radionuclides: State of the Science* Scott H. Britz-Cunningham, MD, PhD; and S. James Adelstein, MD, PhD Joint Program in Nuclear Medicine, Harvard Medical School, and Department of Radiology, Brigham and Women’s Hospital, Boston, Massachusetts foundly, if not unrecognizably, altered in the not-too-distant Inherent in the application of advances in biomedical science to future. nuclear medicine is the concept of molecular targeting: the in vivo concentration of labeled tracer by a gene, its transcribed WHAT IS MOLECULAR TARGETING? DNA, or its protein product. This mechanism of localization has been and is being exploited for both nuclear imaging and ra- “Molecular targeting” may be defined as the specific dioisotopic therapy. Agents, such as antisense molecules, concentration of a diagnostic tracer or therapeutic agent by aptamers, antibodies, and antibody fragments, can be aimed at virtue of its interaction with a molecular species that is molecular targets. Tumor and nerve cell receptors provide such distinctly present or absent in a disease state. The molecular targets. So do certain cellular physiologic activities, including species in question could be a mutated locus of DNA or its metabolism, hypoxia, proliferation, apoptosis, angiogenesis, re- sponse to infection, and multiple drug resistance. In this article protein or RNA product; a gene product of normal sequence we review the principles of molecular targeting based on radio- and structure, aberrantly expressed in a given tissue; or a isotopic methods and provide examples from the literature. We transcriptionally normal gene product whose structure or discuss applications to imaging and therapy and point out the function has been modified by abnormal RNA splicing or hurdles that must be overcome in bringing molecular targeting posttranslational processing.
    [Show full text]
  • Drug Development in Alzheimer's Disease: the Contribution of PET and SPECT
    fphar-07-00088 March 29, 2016 Time: 15:21 # 1 View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector REVIEW published: 31 March 2016 doi: 10.3389/fphar.2016.00088 Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT Lieven D. Declercq1, Rik Vandenberghe2, Koen Van Laere3, Alfons Verbruggen1 and Guy Bormans1* 1 Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, 2 Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium, 3 Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium Clinical trials aiming to develop disease-altering drugs for Alzheimer’s disease (AD), a neurodegenerative disorder with devastating consequences, are failing at an alarming rate. Poorly defined inclusion-and outcome criteria, due to a limited amount of objective biomarkers, is one of the major concerns. Non-invasive molecular imaging techniques, positron emission tomography and single photon emission (computed) tomography (PET and SPE(C)T), allow visualization and quantification of a wide variety of (patho)physiological processes and allow early (differential) diagnosis in many disorders. Edited by: Albert D. Windhorst, PET and SPECT have the ability to provide biomarkers that permit spatial assessment VU University Medical Center, of pathophysiological molecular changes and therefore objectively evaluate and follow Netherlands up therapeutic response, especially in the brain. A number of specific PET/SPECT Reviewed by: biomarkers used in support of emerging clinical therapies in AD are discussed in this Bashir M. Rezk, Southern University at New Orleans, review.
    [Show full text]
  • Sustained Recreational Use of Ecstasy Is Associated with Altered
    Neuropsychopharmacology (2012) 37, 1465–1473 & 2012 American College of Neuropsychopharmacology. All rights reserved 0893-133X/12 www.neuropsychopharmacology.org Sustained Recreational Use of Ecstasy Is Associated with Altered Pre and Postsynaptic Markers of Serotonin Transmission in Neocortical Areas: A PET Study with [11C]DASB and [11C]MDL 100907 ,1,4 1,4 2 1 1 3 Nina BL Urban* , Ragy R Girgis , Peter S Talbot , Lawrence S Kegeles ,XXu, W Gordon Frankle , Carl L Hart1, Mark Slifstein1, Anissa Abi-Dargham1 and Marc Laruelle1 1 2 Department of Psychiatry, Columbia University, New York State Psychiatric Institute, New York, NY, USA; Department of Psychiatry, University 3 of Manchester, Manchester, UK; Department of Psychiatry, University of Pittsburgh, PA, USA 3,4-Methylenedioxymethamphetamine (MDMA), the main psychoactive component of the recreational drug ecstasy, is a potent serotonin (5-HT) releaser. In animals, MDMA induces 5-HT depletion and toxicity in 5-HT neurons. The aim of this study was to investigate both presynaptic (5-HT transporter, SERT) and postsynaptic (5-HT2A receptor) markers of 5-HT transmission in recently abstinent chronic MDMA users compared with matched healthy controls. We hypothesized that MDMA use is associated with lower SERT density and concomitant upregulation of 5-HT2A receptors. Positron emission tomography studies using the SERT ligand 11 11 [ C]DASB and the 5-HT2A receptor ligand [ C]MDL 100907 were evaluated in 13 current and recently detoxified MDMA users and 13 matched healthy controls. MDMA users reported a mean duration of ecstasy use of 8 years, regular exposure, and at least 2 weeks of abstinence before the scans.
    [Show full text]
  • Serotonin Transporter Occupancy with Tcas and Ssris: a PET Study in Patients with Major Depressive Disorder
    International Journal of Neuropsychopharmacology (2012), 15, 1167–1172. f CINP 2012 BRIEF REPORT doi:10.1017/S1461145711001945 Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder Johan Lundberg, Mikael Tiger, Mikael Lande´n, Christer Halldin and Lars Farde Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden Abstract The aim of the present clinical positron emission tomography study was to examine if the 5-HTT is a common target, both for tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). Serotonin transporter (5-HTT) occupancy was estimated during treatment with TCA, SSRI and mirtazapine in 20 patients in remission from depression. The patients were recruited from out-patient units and deemed as responders to antidepressive treatment. The radioligand [11C]MADAM was used to determine the 5-HTT binding potential. The mean 5-HTT occupancy was 67% (range 28–86%). There was no significant difference in 5-HTT occupancy between TCA (n=5) and SSRI (n=14). 5-HTT affinity correlated with the recommended clinical dose. Mirtazapine did not occupy the serotonin transporter. The results support that TCAs and SSRIs have a shared mechanism of action by inhibition of 5-HTT. Received 13 November 2011; Reviewed 7 December 2011; Accepted 7 December 2011; First published online 16 January 2012 Key words: 5-HTT, depression, PET, SSRI, TCA. Introduction Molecular imaging methods such as positron emission tomography (PET) allow for measurement of The era of pharmacological treatment of depression drug binding to target proteins in the human brain. began with the tricyclic antidepressant (TCA), Recent advancements include the development of the imipramine, which was found to be effective in the radioligand [11C]DASB, for selective imaging of 5-HTT treatment of endogenous depression (Kuhn, 1958).
    [Show full text]